Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Cholangiocarcinoma 10Acrocephalosyndactylia 6Carcinoma, Transitional Cell 5Neoplasm Metastasis 4Breast Neoplasms 4Gastrointestinal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Solid Tumor 2Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Myeloproliferative Disorders 2Lung Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma 2Urinary Bladder Neoplasms 1Solid Tumor, Miscellaneous 1Sarcoma 1Oligodendroglioma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Unknown Primary 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Locally Advanced Unresectable Gastric Cancer 1Liposarcoma 1Leukemia, Myeloid, Acute 1

Interventions

Docetaxel 6Gemcitabine 3Carboplatin 3lorlatinib 2cemiplimab 2Vinorelbine 2S 1 (combination) 2Pemetrexed 2Erlotinib Hydrochloride 2Cisplatin 2Cetuximab 2zimberelimab 1surufatinib 1sintilimab 1quemliclustat 1pemigatinib 1pembrolizumab 1nimotuzumab 1fludarabine 1WW Domain-Containing Oxidoreductase 1Paclitaxel 1Interleukin-2 1Gene Expression Profiling 1Drug Therapy 1Cyclophosphamide 1Capecitabine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Non-Small Cell Lung Cancer × pemigatinib × Clear all
NCT05287386 2022-03-18

A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy

The First Affiliated Hospital of Xiamen University

Phase 2 Unknown
20 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡